Histone Deacetylase 2 (Transcriptional Regulator Homolog RPD3 or YY1-Associated Factor 1 or EC 3.5.1.98) - Pipeline Review, H1 2016

Published: Jun, 2016 | Pages: 92 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Histone Deacetylase 2 (Transcriptional Regulator Homolog RPD3 or YY1-Associated Factor 1 or EC 3.5.1.98) - Pipeline Review, H1 2016

Summary

Global Markets Direct's, 'Histone Deacetylase 2 (Transcriptional Regulator Homolog RPD3 or YY1-Associated Factor 1 or EC 3.5.1.98) - Pipeline Review, H1 2016', provides in depth analysis on Histone Deacetylase 2 (Transcriptional Regulator Homolog RPD3 or YY1-Associated Factor 1 or EC 3.5.1.98) targeted pipeline therapeutics. 

The report provides comprehensive information on the Histone Deacetylase 2 (Transcriptional Regulator Homolog RPD3 or YY1-Associated Factor 1 or EC 3.5.1.98), targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Histone Deacetylase 2 (Transcriptional Regulator Homolog RPD3 or YY1-Associated Factor 1 or EC 3.5.1.98) targeted therapeutics development and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape for Histone Deacetylase 2 (Transcriptional Regulator Homolog RPD3 or YY1-Associated Factor 1 or EC 3.5.1.98)
- The report reviews Histone Deacetylase 2 (Transcriptional Regulator Homolog RPD3 or YY1-Associated Factor 1 or EC 3.5.1.98) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources 
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages 
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved in Histone Deacetylase 2 (Transcriptional Regulator Homolog RPD3 or YY1-Associated Factor 1 or EC 3.5.1.98) targeted therapeutics and enlists all their major and minor projects 
- The report assesses Histone Deacetylase 2 (Transcriptional Regulator Homolog RPD3 or YY1-Associated Factor 1 or EC 3.5.1.98) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type 
- The report summarizes all the dormant and discontinued pipeline projects 
- The report reviews latest news and deals related to Histone Deacetylase 2 (Transcriptional Regulator Homolog RPD3 or YY1-Associated Factor 1 or EC 3.5.1.98) targeted therapeutics

Reasons To Buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage 
- Identify and understand the targeted therapy areas and indications for Histone Deacetylase 2 (Transcriptional Regulator Homolog RPD3 or YY1-Associated Factor 1 or EC 3.5.1.98)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies 
- Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Histone Deacetylase 2 (Transcriptional Regulator Homolog RPD3 or YY1-Associated Factor 1 or EC 3.5.1.98) development landscape 
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

 Table of Contents

Table of Contents 2
List of Tables 6
List of Figures 7
Introduction 8
Global Markets Direct Report Coverage 8
Histone Deacetylase 2 (Transcriptional Regulator Homolog RPD3 or YY1-Associated Factor 1 or EC 3.5.1.98) Overview 9
Therapeutics Development 10
Histone Deacetylase 2 (Transcriptional Regulator Homolog RPD3 or YY1-Associated Factor 1 or EC 3.5.1.98) - Products under Development by Stage of Development 10
Histone Deacetylase 2 (Transcriptional Regulator Homolog RPD3 or YY1-Associated Factor 1 or EC 3.5.1.98) - Products under Development by Therapy Area 11
Histone Deacetylase 2 (Transcriptional Regulator Homolog RPD3 or YY1-Associated Factor 1 or EC 3.5.1.98) - Products under Development by Indication 12
Histone Deacetylase 2 (Transcriptional Regulator Homolog RPD3 or YY1-Associated Factor 1 or EC 3.5.1.98) - Pipeline Products Glance 14
Late Stage Products 14
Early Stage Products 15
Histone Deacetylase 2 (Transcriptional Regulator Homolog RPD3 or YY1-Associated Factor 1 or EC 3.5.1.98) - Products under Development by Companies 16
Histone Deacetylase 2 (Transcriptional Regulator Homolog RPD3 or YY1-Associated Factor 1 or EC 3.5.1.98) - Products under Development by Universities/Institutes 21
Histone Deacetylase 2 (Transcriptional Regulator Homolog RPD3 or YY1-Associated Factor 1 or EC 3.5.1.98) - Therapeutics Assessment 23
Assessment by Monotherapy/Combination Products 23
Assessment by Mechanism of Action 24
Assessment by Route of Administration 26
Assessment by Molecule Type 28
Histone Deacetylase 2 (Transcriptional Regulator Homolog RPD3 or YY1-Associated Factor 1 or EC 3.5.1.98) - Companies Involved in Therapeutics Development 29
4SC AG 29
Acetylon Pharmaceuticals, Inc. 30
Chipscreen Biosciences Ltd 31
Curis, Inc. 32
GlaxoSmithKline Plc 33
HitGen LTD 34
Italfarmaco S.p.A. 35
MEI Pharma, Inc. 36
Merck & Co., Inc. 37
Rodin Therapeutics 38
Sigma-Tau S.p.A. 39
TetraLogic Pharmaceuticals 40
Yungjin Pharm. Co., Ltd. 41
Histone Deacetylase 2 (Transcriptional Regulator Homolog RPD3 or YY1-Associated Factor 1 or EC 3.5.1.98) - Drug Profiles 42
4SC-202 - Drug Profile 42
Product Description 42
Mechanism Of Action 42
R&D Progress 42
ACY-738 - Drug Profile 45
Product Description 45
Mechanism Of Action 45
R&D Progress 45
ACY-957 - Drug Profile 46
Product Description 46
Mechanism Of Action 46
R&D Progress 46
chidamide - Drug Profile 48
Product Description 48
Mechanism Of Action 48
R&D Progress 48
CS-3158 - Drug Profile 51
Product Description 51
Mechanism Of Action 51
R&D Progress 51
CUDC-907 - Drug Profile 52
Product Description 52
Mechanism Of Action 52
R&D Progress 52
givinostat - Drug Profile 57
Product Description 57
Mechanism Of Action 57
R&D Progress 57
HG-3001 - Drug Profile 59
Product Description 59
Mechanism Of Action 59
R&D Progress 59
Largazole - Drug Profile 60
Product Description 60
Mechanism Of Action 60
R&D Progress 60
N-140 - Drug Profile 61
Product Description 61
Mechanism Of Action 61
R&D Progress 61
pracinostat - Drug Profile 62
Product Description 62
Mechanism Of Action 62
R&D Progress 62
remetinostat - Drug Profile 67
Product Description 67
Mechanism Of Action 67
R&D Progress 67
Small Molecule to Inhibit HDAC2 for Oncology - Drug Profile 69
Product Description 69
Mechanism Of Action 69
R&D Progress 69
Small Molecule to Inhibit Histone Deacetylases for Oncology - Drug Profile 70
Product Description 70
Mechanism Of Action 70
R&D Progress 70
Small Molecules to Inhibit HDAC2 for Neurological Disorders - Drug Profile 71
Product Description 71
Mechanism Of Action 71
R&D Progress 71
ST-3595 - Drug Profile 72
Product Description 72
Mechanism Of Action 72
R&D Progress 72
vorinostat - Drug Profile 73
Product Description 73
Mechanism Of Action 73
R&D Progress 73
YPL-001 - Drug Profile 77
Product Description 77
Mechanism Of Action 77
R&D Progress 77
Histone Deacetylase 2 (Transcriptional Regulator Homolog RPD3 or YY1-Associated Factor 1 or EC 3.5.1.98) - Dormant Projects 78
Histone Deacetylase 2 (Transcriptional Regulator Homolog RPD3 or YY1-Associated Factor 1 or EC 3.5.1.98) - Featured News & Press Releases 81
Jun 08, 2016: Curis Announces Oral Presentation of Clinical Data Update from the Phase 1 Study of CUDC-907 at the 21st Congress of the European Hematology Association 81
Jun 02, 2016: Curis Announces Presentations Related to CUDC-907 at 2016 ASCO Annual Meeting 81
May 04, 2016: Acetylon Pharmaceuticals Publishes New Mechanism for the Treatment of Sickle Cell Disease/Beta-Thalassemia with Selective HDAC1/2 Inhibition in PLoS One 81
Apr 11, 2016: Curis Announces Presentation of Preclinical Data for CUDC-907 at AACR Annual Meeting 82
Apr 04, 2016: Curis Announces Publication of CUDC-907 Phase 1 Clinical Trial Data in Lancet Oncology 83
Mar 21, 2016: Epigenetic compound 4SC-202 strengthens endogenous immune response to cancer 83
Mar 03, 2016: HUYA Bioscience International Expands Senior Management Team 84
Dec 22, 2015: Huya Bioscience International Announces Orphan Drug Designation For HBI-8000 In Japan 84
Dec 07, 2015: MEI Pharma Announces Positive Results from Phase II Study of Pracinostat in Acute Myeloid Leukemia, Plans to Initiate Phase III Registration Study 84
Dec 07, 2015: Acetylon Presents Data on the Pharmacokinetics and HbE/HbG Hemoglobin Induction Following Once Daily Dosing of an Oral HDAC1,2 Inhibitor in Animal Models 85
Dec 06, 2015: Curis Reports Clinical Activity of CUDC-907 in Patients With DLBCL Harboring MYC Oncogene Alterations at the 2015 ASH Annual Meeting 86
Nov 05, 2015: Curis Announces Oral Presentation of Phase 1 Data for CUDC-907 at 2015 ASH Annual Meeting 88
Nov 02, 2015: TetraLogic Announces the Opening of an IND for SHAPE Gel in Alopecia Areata 89
Oct 06, 2015: MEI Pharma Announces Data from Phase II Clinical Studies of Pracinostat Accepted for Oral Presentation at American Society of Hematology Annual Meeting 89
Sep 30, 2015: 4SC receives funding from the Eurostars programme for further research of its anti-cancer agent 4SC-202 with an epigenetic mode of action 89
Appendix 91
Methodology 91
Coverage 91
Secondary Research 91
Primary Research 91
Expert Panel Validation 91
Contact Us 91
Disclaimer 92

List of Tables

Number of Products under Development for, H1 2016 10
Number of Products under Development by Therapy Area, H1 2016 11
Number of Products under Development by Indication, H1 2016 12
Comparative Analysis by Late Stage Development, H1 2016 14
Comparative Analysis by Early Stage Products, H1 2016 15
Number of Products under Development by Companies, H1 2016 16
Products under Development by Companies, H1 2016 17
Products under Development by Companies, H1 2016 (Contd..1) 18
Products under Development by Companies, H1 2016 (Contd..2) 19
Products under Development by Companies, H1 2016 (Contd..3) 20
Number of Products under Investigation by Universities/Institutes, H1 2016 21
Products under Investigation by Universities/Institutes, H1 2016 22
Assessment by Monotherapy/Combination Products, H1 2016 23
Number of Products by Stage and Mechanism of Action, H1 2016 25
Number of Products by Stage and Route of Administration, H1 2016 27
Number of Products by Stage and Molecule Type, H1 2016 28
Pipeline by 4SC AG, H1 2016 29
Pipeline by Acetylon Pharmaceuticals, Inc., H1 2016 30
Pipeline by Chipscreen Biosciences Ltd, H1 2016 31
Pipeline by Curis, Inc., H1 2016 32
Pipeline by GlaxoSmithKline Plc, H1 2016 33
Pipeline by HitGen LTD, H1 2016 34
Pipeline by Italfarmaco S.p.A., H1 2016 35
Pipeline by MEI Pharma, Inc., H1 2016 36
Pipeline by Merck & Co., Inc., H1 2016 37
Pipeline by Rodin Therapeutics, H1 2016 38
Pipeline by Sigma-Tau S.p.A., H1 2016 39
Pipeline by TetraLogic Pharmaceuticals, H1 2016 40
Pipeline by Yungjin Pharm. Co., Ltd., H1 2016 41
Dormant Projects, H1 2016 78
Dormant Projects (Contd..1), H1 2016 79
Dormant Projects (Contd..2), H1 2016 80